{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:38:01Z","timestamp":1793090281305,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2024ZZTS0318"],"award-info":[{"award-number":["2024ZZTS0318"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"The Mark Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105517","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:31:12Z","timestamp":1786033872000},"page":"105517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biomarker-driven insights into immune checkpoint inhibitor therapy in small-cell lung cancer"],"prefix":"10.1016","volume":"227","author":[{"given":"Shuxing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine Lai-Han","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Png","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoxi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijiao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward E.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Sage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-3437","authenticated-orcid":false,"given":"Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: Epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection","volume":"18","author":"Wang","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105517_bib2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"Jama"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105517_bib3","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105517_bib4","doi-asserted-by":"crossref","unstructured":"Leal, T., et al., Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. Journal of Clinical Oncology. 38(15_suppl) n.d.: p. 9000-9000.","DOI":"10.1200\/JCO.2020.38.15_suppl.9000"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105517_bib5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105517_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol."},{"issue":"10212","key":"10.1016\/j.critrevonc.2026.105517_bib8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105517_bib9","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105517_bib10","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105517_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-025-00992-5","article-title":"The current and emerging immunotherapy paradigm in small-cell lung cancer","author":"Qin","year":"2025","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105517_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105517_bib13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12943-024-02014-x","article-title":"Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study","volume":"23","author":"Xie","year":"2024","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105517_bib15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105517_bib16","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jtho.2023.05.008","article-title":"Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation","volume":"18","author":"Rudin","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105517_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105062","article-title":"Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer","volume":"102","author":"Park","year":"2024","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105517_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","article-title":"Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade","volume":"42","author":"Nabet","year":"2024","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1186\/s12967-025-06724-8","article-title":"Immune profiling identifies CD161(+)CD127(+)CD8(+) T cells as a predictive biomarker for Anti-PD-L1 therapy response in the SCLC-I subtype","volume":"23","author":"Qu","year":"2025","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105517_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00262-025-04068-2","article-title":"Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC","volume":"74","author":"Zhang","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105517_bib21","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/1878-0261.12741","article-title":"Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution","volume":"14","author":"Dora","year":"2020","journal-title":"Mol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105517_bib22","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","article-title":"Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer","volume":"39","author":"Chan","year":"2021","journal-title":"Cancer Cell."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105517_bib23","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-24-0104","article-title":"Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer","volume":"30","author":"Peressini","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105517_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/s41419-023-06053-y","article-title":"YAP1 expression is associated with survival and immunosuppression in small cell lung cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Cell. Death Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s12890-024-03221-4","article-title":"Characteristics of molecular subtypes and cinical outcomes in the immunotherapy Queue of extensive-stage small cell lung cancer patients","volume":"24","author":"Li","year":"2024","journal-title":"BMC Pulm. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105517_bib26","article-title":"Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer","volume":"22","author":"Huo","year":"2024","journal-title":"Genom. Proteom. Bioinforma."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105517_bib27","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jtho.2023.07.012","article-title":"Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry","volume":"18","author":"Pearsall","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105517_bib28","article-title":"Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small-cell lung cancer","volume":"7","author":"Wang","year":"2026","journal-title":"Cell. Rep. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41540-023-00316-2","article-title":"Data-driven structural analysis of small cell lung cancer transcription factor network suggests potential subtype regulators and transition pathways","volume":"9","author":"Ozen","year":"2023","journal-title":"NPJ Syst. Biol. Appl."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105517_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.70001","article-title":"The expression of YAP1 and other transcription factors contributes to lineage plasticity in combined small cell lung carcinoma","volume":"10","author":"Jimbo","year":"2024","journal-title":"J. Pathol. Clin. Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105517_bib31","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41416-026-03414-0","article-title":"Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed\/refractory small-cell lung cancer","volume":"134","author":"Johnson","year":"2026","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105517_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00257","article-title":"Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function","author":"Dowlati","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105517_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04439","article-title":"Detection of somatic TP53 mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survival","volume":"6","author":"Yokouchi","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2026.105517_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112901","article-title":"Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy","volume":"141","author":"Jiang","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105517_bib35","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jtho.2023.06.009","article-title":"SCLC Subtypes and Biomarkers of the Transformative Immunotherapy Responses","volume":"18","author":"Schroeder","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib36","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1038\/s41467-021-24164-y","article-title":"Notch signaling and efficacy of PD-1\/PD-L1 blockade in relapsed small cell lung cancer","volume":"12","author":"Roper","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105517_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185423","article-title":"NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING","author":"Kim","year":"2025","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105517_bib38","doi-asserted-by":"crossref","first-page":"640","DOI":"10.14336\/AD.2023.0520","article-title":"MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products","volume":"15","author":"Chan","year":"2024","journal-title":"Aging Dis."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105517_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38572","article-title":"Potential immunologic and prognostic roles of CHRNA6 in SCLC and pan-cancer","volume":"10","author":"Zhao","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-025-01667-5","article-title":"Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer","volume":"18","author":"Yoo","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105517_bib41","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.932275","article-title":"Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer","volume":"27","author":"Gao","year":"2021","journal-title":"Med. Sci. Monit."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105517_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00262-024-03829-9","article-title":"A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients","volume":"73","author":"Jiang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105517_bib43","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/annonc\/mdw005","article-title":"Clinical correlation of extensive-stage small-cell lung cancer genomics","volume":"27","author":"Dowlati","year":"2016","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105517_bib44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccell.2025.01.012","article-title":"Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105517_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2024.10.021","article-title":"Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929","volume":"20","author":"Karim","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105517_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26136095","article-title":"MET and SLFN11 as a Players in the SCLC Molecular Subtyping Game","volume":"26","author":"Grenda","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105517_bib47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00262-025-03985-6","article-title":"Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response","volume":"74","author":"Liu","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"7563","key":"10.1016\/j.critrevonc.2026.105517_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105517_bib49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ccell.2019.01.011","article-title":"Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer","volume":"35","author":"Hellmann","year":"2019","journal-title":"Cancer Cell."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105517_bib50","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105517_bib51","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105517_bib52","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105517_bib53","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105517_bib54","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies","volume":"15","author":"Chung","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105517_bib55","article-title":"Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study","volume":"2","author":"Akamatsu","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.critrevonc.2026.105517_bib56","article-title":"A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy","author":"Musicco","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105517_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2019.02.003","article-title":"Prolonged release of metformin by SiO(2) nanoparticles pellets for type II diabetes control","volume":"131","author":"Patino-Herrera","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105517_bib59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.21037\/tlcr-23-696","article-title":"Systemic immune index predicts tumor-infiltrating lymphocyte intensity and immunotherapy response in small cell lung cancer","volume":"13","author":"Deng","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105517_bib60","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2023.12.015","article-title":"IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction","volume":"80","author":"Shiri","year":"2024","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105517_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.27613","article-title":"Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate","volume":"131","author":"Wang","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105517_bib62","article-title":"CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer","volume":"9","author":"Tang","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105517_bib63","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7150\/jca.22656","article-title":"Serum expression level of IL-6 at the diagnosis time contributes to the long-term prognosis of SCLC patients","volume":"9","author":"Ding","year":"2018","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105517_bib64","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593810","article-title":"Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer","volume":"8","author":"Hardy-Werbin","year":"2019","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105517_bib65","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593810","article-title":"Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer","volume":"8","author":"Hardy-Werbin","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105517_bib66","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-3-319-55947-6_12","article-title":"Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer","volume":"994","author":"Hamilton","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105517_bib67","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.7150\/jca.35308","article-title":"Circulating tumor cells as a new predictive and prognostic factor in patients with small cell lung cancer","volume":"11","author":"Wang","year":"2020","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12010146","article-title":"ES-SCLC Patients with PD-L1(+) CTCs and High Percentages of CD8(+)PD-1(+)T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment","volume":"12","author":"Xagara","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105517_bib69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.lungcan.2023.01.015","article-title":"Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer","volume":"178","author":"Zhang","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105517_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102795","article-title":"Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC): a phase II trial","volume":"75","author":"Chen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105517_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9123861","article-title":"Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab","volume":"9","author":"Herbreteau","year":"2020","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105517_bib72","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/1078-0432.CCR-23-0420","article-title":"ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?","volume":"29","author":"Pellini","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105517_bib73","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1152\/physrev.00032.2024","article-title":"Extracellular vesicles and the lung: from disease pathogenesis to biomarkers and treatments","volume":"105","author":"Park","year":"2025","journal-title":"Physiol. Rev."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105517_bib74","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41419-022-05336-0","article-title":"NLRP6 is required for cancer-derived exosome-modified macrophage M2 polarization and promotes metastasis in small cell lung cancer","volume":"13","author":"Rao","year":"2022","journal-title":"Cell. Death Dis."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105517_bib75","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/cei\/uxac006","article-title":"Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer","volume":"207","author":"Dou","year":"2022","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105517_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020190","article-title":"Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor\/Chemotherapy","volume":"13","author":"Riemann","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib77","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s40364-024-00713-7","article-title":"Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer","volume":"12","author":"Lee","year":"2024","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib78","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12967-019-02160-7","article-title":"The prognostic role of circulating CD8(+) T cell proliferation in patients with untreated extensive stage small cell lung cancer","volume":"17","author":"An","year":"2019","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105517_bib79","first-page":"592","article-title":"Identification and clinical significance of myeloid-derived suppressor cells in peripheral blood of small-cell lung cancer patients","volume":"36","author":"Cheng","year":"2014","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105517_bib80","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/CBM-150473","article-title":"Increased circulating CD14(+)HLA-DR-\/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer","volume":"15","author":"Tian","year":"2015","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.critrevonc.2026.105517_bib81","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejca.2022.06.020","article-title":"Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma","volume":"172","author":"Dumoulin","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105517_bib82","doi-asserted-by":"crossref","first-page":"257","DOI":"10.21037\/tlcr-22-666","article-title":"Peripheral T-cell receptor repertoire dynamics in small cell lung cancer","volume":"12","author":"Balbach","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105517_bib83","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri1570","article-title":"MHC class I molecules and KIRs in human history, health and survival","volume":"5","author":"Parham","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12943-025-02383-x","article-title":"IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1\/-L1 therapy in SCLC","volume":"24","author":"Cui","year":"2025","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105517_bib85","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/2159-8290.CD-20-0913","article-title":"Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity","volume":"11","author":"Mahadevan","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105517_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105515","article-title":"ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A\u22170201.","volume":"112","author":"Yuan","year":"2025","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105517_bib87","article-title":"Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1","volume":"4","author":"Li","year":"2023","journal-title":"Cell. Rep. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105517_bib88","article-title":"Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer","volume":"5","author":"Chakraborty","year":"2024","journal-title":"Cell. Rep. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105517_bib89","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105517_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110814","article-title":"WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC","volume":"39","author":"Taniguchi","year":"2022","journal-title":"Cell. Rep."},{"issue":"39","key":"10.1016\/j.critrevonc.2026.105517_bib91","doi-asserted-by":"crossref","first-page":"eado4618","DOI":"10.1126\/sciadv.ado4618","article-title":"ATR inhibition activates cancer cell cGAS\/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer","volume":"10","author":"Taniguchi","year":"2024","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105517_bib92","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ccell.2026.02.008","article-title":"Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer","volume":"44","author":"Campisi","year":"2026","journal-title":"Cancer Cell."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105517_bib93","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185423","article-title":"NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING","volume":"135","author":"Kim","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"567","key":"10.1016\/j.critrevonc.2026.105517_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau2922","article-title":"Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition","volume":"12","author":"Augert","year":"2019","journal-title":"Sci. Signal."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105517_bib95","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jtho.2022.05.014","article-title":"Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC","volume":"17","author":"Nguyen","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105517_bib96","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1158\/0008-5472.CAN-24-2772","article-title":"Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy","volume":"85","author":"Redin","year":"2025","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105517_bib97","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.21037\/jtd-24-1201","article-title":"Gut microbiota and metabolites associated with immunotherapy efficacy in extensive-stage small cell lung cancer: a pilot study","volume":"16","author":"Sun","year":"2024","journal-title":"J. Thorac. Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105517_bib98","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/1759-7714.15172","article-title":"Association of antibiotic exposure with survival in patients with extensive-stage small cell lung cancer receiving immune checkpoint inhibitor therapy","volume":"15","author":"Zhong","year":"2024","journal-title":"Thorac. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105517_bib99","doi-asserted-by":"crossref","DOI":"10.1111\/crj.13764","article-title":"Causal influence of gut microbiota on small cell lung cancer: a Mendelian randomization study","volume":"18","author":"Yang","year":"2024","journal-title":"Clin. Respir. J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib100","doi-asserted-by":"crossref","first-page":"10887","DOI":"10.1038\/s41598-020-67843-4","article-title":"The colonic mucosa-associated microbiome in SIV infection: shift towards Bacteroidetes coincides with mucosal CD4(+) T cell depletion and enterocyte damage","volume":"10","author":"Allers","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105517_bib101","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41417-021-00296-7","article-title":"Use of an optimised enzyme\/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours","volume":"29","author":"Mowday","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105517_bib102","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.7150\/ijbs.35980","article-title":"Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer","volume":"15","author":"Liu","year":"2019","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib103","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12931-020-01392-2","article-title":"Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial","volume":"21","author":"Bingula","year":"2020","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib104","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13099-024-00606-y","article-title":"Identification of enterotype and its predictive value for patients with colorectal cancer","volume":"16","author":"Qingbo","year":"2024","journal-title":"Gut Pathog."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105517_bib105","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jtho.2016.05.028","article-title":"Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC","volume":"11","author":"Arriola","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105517_bib106","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/01635581.2024.2392297","article-title":"Association Between Sarcopenia, Clinical Outcomes, and Survival in Patients with Extensive-Stage Small Cell Lung Cancer Treated with First-Line Immunochemotherapy: A Prospective Cohort Study","volume":"77","author":"Tian","year":"2025","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105517_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1439877","article-title":"Unraveling the obesity paradox in small cell lung cancer immunotherapy: unveiling prognostic insights through body composition analysis","volume":"15","author":"Fang","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105517_bib108","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.21037\/tlcr-2025-300","article-title":"Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer","volume":"14","author":"May","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105517_bib109","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105517_bib110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00262-020-02706-5","article-title":"Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1\/PD-L1 antibody in SCLC patients at early phase","volume":"70","author":"Xiong","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105517_bib111","article-title":"A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer","volume":"12","author":"Hsu","year":"2024","journal-title":"Vaccin. (Basel)"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105517_bib112","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1038\/s41591-023-02631-x","article-title":"Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma","volume":"29","author":"Fraterman","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105517_bib113","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-024-02929-4","article-title":"Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer","volume":"30","author":"Zeng","year":"2024","journal-title":"Nat. Med."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105517_bib114","article-title":"Association between psychological distress and treatment efficacy in patients with newly diagnosed SCLC","volume":"42","author":"Wu","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600404X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600404X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:07:10Z","timestamp":1793088430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600404X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":114,"alternative-id":["S104084282600404X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105517","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker-driven insights into immune checkpoint inhibitor therapy in small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105517"}}